The Clinical Conductor Site CTMS development team has just released the third major update of the year. Driven by customer input and a deep understanding of market needs, Clinical Conductor Site has developed a multitude of new features, while enhancing many existing tools.
The Clinical Conductor Site CTMS development team has just released the third major update of the year. Driven by customer input and a deep understanding of market needs, Clinical Conductor Site has developed a multitude of new features, while enhancing many existing tools. This way, Clinical Conductor Site can continue to empower its users to raise the bar in clinical research and remain the only CTMS capable of meeting any challenge.
The Clinical Conductor Site CTMS software development and customer support teams have been hard at work designing and developing an array of features that are designed to simplify the way research sites manage the studies that they are conducting. Just to name a few of the enhancements coming to the application, significant changes have been made to the study visit tracking and patient scheduling portions of the application. Modifications have also been made to the user interface and customization of pages within the application.
One of the major enhancements coming to Clinical Conductor Site is a complete redesign of the patient scheduling functionality in the application. The multiple easy-to-use scheduling methods give research sites the ability to schedule based on their specific needs. These updated tools ensure that patients are never scheduled outside of their visit windows and that patient visits are never missed.
Additional enhancements include modifications to the user interface and layout of commonly used pages to further streamline operations and reduce the number of clicks needed to perform certain activities, saving time and improving intuitiveness. The already high levels of customization found in Clinical Conductor Site have been taken to another level through the addition of configurable management dashboards, which allow for the centralization of key information that each user wants to see, and the addition of completely customizable pages to track patient information, study information and study visits.
"Further solidifying the leadership of Clinical Conductor Site CTMS, the newest release takes our dedication to exceeding expectations to a level never before seen," explains Dan Kerpelman, CEO of Bio-Optronics. "Leveraging the newest technologies, we are able to provide users with a beautiful, intuitive application, while maintaining the expansive feature set that puts Clinical Conductor ahead of any other CTMS."
As Clinical Conductor Site CTMS continues to evolve, users will regularly be consulted to ensure that Clinical Conductor Site continues to exceed expectations. Designed to bring unparalleled benefit to research sites, Clinical Conductor Site is the ultimate tool for streamlining operations and making complex challenges a thing of the past. When coupled with the unmatched level of support provided to users, Clinical Conductor helps to make an already leading product an even greater asset for research sites of all sizes. With Clinical Conductor Site CTMS research sites can improve their business and clinical operations and achieve their true potential.
Investigational Pain Therapy Cebranopadol Succeeds in Second Phase III Clinical Trial
March 6th 2025Tris Pharma’s first-in-class oral dual-NMR agonist achieved its primary endpoint in the ALLEVIATE-2 study by demonstrating a statistically significant and high level of pain reduction compared to placebo.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
Reaching Diverse Patient Populations With Personalized Treatment Methods
January 20th 2025Daejin Abidoye, head of solid tumors, oncology development, AbbVie, discusses a number of topics around diversity in clinical research including industry’s greatest challenges in reaching diverse patient populations, personalized treatment methods, recruitment strategies, and more.
Xolair Outperforms Oral Immunotherapy in Landmark Phase III OUtMATCH Food Allergy Trial
March 3rd 2025Xolair (omalizumab) shows superior efficacy and safety compared to multi-allergen oral immunotherapy in treating food allergies in the Phase III OUtMATCH trial, suggesting the potential to facilitate the introduction of allergenic foods into patients' diets after treatment.